An old drug supercharged by University of Queensland researchers has emerged as a new antibiotic that could destroy some of the world’s most dangerous superbugs.
The supercharge technique , led by Dr Mark Blaskovich and Professor Matt Cooper from UQ’s Institute for Molecular Bioscience (IMB), potentially could revitalise other antibiotics. Continue reading Supercharged antibiotics could turn tide against superbugs
Cystic fibrosis care has seen such rapid advances that the average CF patient has experienced a dramatic evolution in treatment strategies in their lifetime. Here are some of the biggest milestones that shaped modern-day CF treatments.
Continue reading A Brief Historical Timeline of CF Research to Date
Polyphor launches the development of an inhaled antibiotic murepavadin
Polyphor Ltd has announced the development of an inhaled dosage form of its breakthrough antibiotic Murepavadin. Continue reading New Inhaled Antibiotic To Treat Respiratory Infections
Motif Bio Presents New Pre-Clinical Data for Iclaprim at IDWeek 2017™
1. Pre-Clinical Data Support the Potential Use of Iclaprim in the Treatment of Staphylococcus aureus Pneumonia in Cystic Continue reading New Pre-Clinical Data for Iclaprim
With antibiotic-resistant “superbugs” continuing to be a threat in U.S. hospitals, doctors are looking for innovative ways to cut down on disease transmission. Continue reading Docs May Have Trick Up Their Sleeves Fighting Germs
Published: Aug. 29, 2017
Michael Maiden, a Michigan State University College of Osteopathic Medicine student and doctoral candidate in the Department of Microbiology and Molecular Genetics, was Continue reading Fighting an old enemy in the battle against cystic fibrosis
AIT Therapeutics Announces Enrollment of First Patient into Its NO-NTM abscessus Phase 2 Trial in Nontuberculous Mycobacteria (NTM)
10 patients with Mycobacterium Abscessus Complex (MABSC) are expected to enroll in the trial Continue reading Phase Two Clinical Trials to treat NTM
Originally published on Cystic Fibrosis Today Website 7/31/17
By Reid D’Amico
Synspira’s CF Therapy May Be Game-Changer for Drug-Resistant Bacteria
Chronic pulmonary infections are a hallmark of lung disease in patients with cystic fibrosis. Due to the variability in bacteria that can colonize the lung and Continue reading News on new drug to treat B. Cepacia
CARB-X has awarded $8.9M (€7.6M) to Antabio for the development of a new antibiotic against resistant Pseudomonas infections in cystic fibrosis patients.
Antabio is a French company developing new antibiotics to fight the rapidly Continue reading French Biotech Receives an Award to Develop a Novel Cystic Fibrosis Antibiotic